Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
Authors
Liabeuf, SophiePepin, , Marion
Franssen, Casper F.M.
Viggiano, Davide
Carriazo, Sol
Gansevoort, Ron T.
Gesualdo, Loreto
Hafez, Gaye
Malyszko, Jolanta
Mayer, Christopher
Nitsch, Dorothea
Ortiz, Alberto
Pešić, Vesna

Wiecek, Andrzej
Massy, Ziad
Article (Published version)
Metadata
Show full item recordAbstract
Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might ...facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins' putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care.
Keywords:
cardiovascular / CKD / indoxyl sulphate / stroke / uraemic toxinsSource:
Nephrology Dialysis Transplantation, 2022, 37, supplement 2, ii33-ii44Publisher:
- Oxford University Press
Funding / projects:
- COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT).
DOI: 10.1093/ndt/gfab223
ISSN: 0931-0509
WoS: 000740945100005
Scopus: 2-s2.0-85123025309
Collections
Institution/Community
PharmacyTY - JOUR AU - Liabeuf, Sophie AU - Pepin, , Marion AU - Franssen, Casper F.M. AU - Viggiano, Davide AU - Carriazo, Sol AU - Gansevoort, Ron T. AU - Gesualdo, Loreto AU - Hafez, Gaye AU - Malyszko, Jolanta AU - Mayer, Christopher AU - Nitsch, Dorothea AU - Ortiz, Alberto AU - Pešić, Vesna AU - Wiecek, Andrzej AU - Massy, Ziad PY - 2022 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4029 AB - Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins' putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care. PB - Oxford University Press T2 - Nephrology Dialysis Transplantation T1 - Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle? VL - 37 IS - supplement 2 SP - ii33 EP - ii44 DO - 10.1093/ndt/gfab223 ER -
@article{ author = "Liabeuf, Sophie and Pepin, , Marion and Franssen, Casper F.M. and Viggiano, Davide and Carriazo, Sol and Gansevoort, Ron T. and Gesualdo, Loreto and Hafez, Gaye and Malyszko, Jolanta and Mayer, Christopher and Nitsch, Dorothea and Ortiz, Alberto and Pešić, Vesna and Wiecek, Andrzej and Massy, Ziad", year = "2022", abstract = "Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins' putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care.", publisher = "Oxford University Press", journal = "Nephrology Dialysis Transplantation", title = "Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?", volume = "37", number = "supplement 2", pages = "ii33-ii44", doi = "10.1093/ndt/gfab223" }
Liabeuf, S., Pepin, ,. M., Franssen, C. F.M., Viggiano, D., Carriazo, S., Gansevoort, R. T., Gesualdo, L., Hafez, G., Malyszko, J., Mayer, C., Nitsch, D., Ortiz, A., Pešić, V., Wiecek, A.,& Massy, Z.. (2022). Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. in Nephrology Dialysis Transplantation Oxford University Press., 37(supplement 2), ii33-ii44. https://doi.org/10.1093/ndt/gfab223
Liabeuf S, Pepin ,M, Franssen CF, Viggiano D, Carriazo S, Gansevoort RT, Gesualdo L, Hafez G, Malyszko J, Mayer C, Nitsch D, Ortiz A, Pešić V, Wiecek A, Massy Z. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. in Nephrology Dialysis Transplantation. 2022;37(supplement 2):ii33-ii44. doi:10.1093/ndt/gfab223 .
Liabeuf, Sophie, Pepin, , Marion, Franssen, Casper F.M., Viggiano, Davide, Carriazo, Sol, Gansevoort, Ron T., Gesualdo, Loreto, Hafez, Gaye, Malyszko, Jolanta, Mayer, Christopher, Nitsch, Dorothea, Ortiz, Alberto, Pešić, Vesna, Wiecek, Andrzej, Massy, Ziad, "Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?" in Nephrology Dialysis Transplantation, 37, no. supplement 2 (2022):ii33-ii44, https://doi.org/10.1093/ndt/gfab223 . .